Adjusting Health Expenditures for Inflation: A Review of Measures for Health Services Research in the United States

Dunn, Abe; Grosse, Scott D.; Zuvekas, Samuel H.

doi:10.1111/1475-6773.12612

Cited by 360 publications

(255 citation statements)

References 36 publications

Supporting

Mentioning

254

Contrasting

Order By: Relevance

“…6 It also included costs to families as well as costs to employer plans, although out-of-pocket expenditures by enrollees raised incremental expenditures in the current study by just 2%. Additionally, the comparison group was restricted to “healthy” term infants, whose mean expenditure in 2013 and 2014 dollars 22 was 39% lower than the average expenditure for nonpreterm infants in the current study. Finally, the March of Dimes estimate included both LBW and preterm infants.…”

Section: Discussionmentioning

confidence: 99%

“…5 The average medical cost for all preterm infants during the birth year in the IOM study was $29 041 in 2005 dollars, 5 which, adjusted for 2013 and 2014 medical prices, 22 is equivalent to $35 527. Applying the gestational age composition of 2013 births 1 to the stratified cost estimates in the IOM report 5 yields a birth year cost estimate for 2013 births of $37 868.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Employer-Sponsored Plan Expenditures for Infants Born Preterm

et al. 2017

Self Cite

View full text Add to dashboard Cite

BACKGROUND Care for infants born preterm or with major birth defects is costly. Specific estimates of financial burden for different payers are lacking, in part because use of administrative data to identify preterm infants and costs is challenging. METHODS We used private health insurance claims data and billing codes to identify live births during 2013 and calculated first-year expenditures for employer-sponsored health plans for infants born preterm, both overall and stratified by major birth defects. RESULTS We conservatively estimated that 7.7% of insured infants born preterm accounted for 37% of $2.0 billion spent by participating plans on the care of infants born during 2013. With a mean difference in plan expenditures of ~$47 100 per infant, preterm births cost the included plans an extra $600 million during the first year of life. Extrapolating to the national level, we projected aggregate employer-sponsored plan expenditures of $6 billion for infants born preterm during 2013. Infants with major birth defects accounted for 5.8% of preterm births but 24.5% of expenditures during infancy. By using an alternative algorithm to identify preterm infants, it was revealed that incremental expenditures were higher: $78 000 per preterm infant and $14 billion nationally. CONCLUSION Preterm births (especially in conjunction with major birth defects) represent a substantial burden on payers, and efforts to mitigate this burden are needed. In addition, researchers need to conduct studies using linked vital records, birth defects surveillance, and administrative data to accurately and longitudinally assess per-infant costs attributable to preterm birth and the interaction of preterm birth with major birth defects.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Employer-Sponsored Plan Expenditures for Infants Born Preterm

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…We calculated spending across all buprenorphine products and separately by buprenorphine product category. All spending estimates were inflated to 2015 dollars by using the medical care component of the Consumer Price Index (8,9). In sensitivity analyses, we examined mean spending, and results were similar (not shown).…”

Section: Methodsmentioning

confidence: 99%

Buprenorphine Use and Spending for Opioid Use Disorder Treatment: Trends From 2003 to 2015

Roberts

Saloner

Dusetzina

2018

View full text Add to dashboard Cite

Objective This study examined buprenorphine prescription uptake and expenditure trends among privately insured adults from 2003 to 2015 to inform efforts to expand opioid use disorder treatment. Methods A study with a repeated cross-sectional design using MarketScan prescription claims data was conducted to describe trends in total and new buprenorphine use and median total, plan, and out-of-pocket expenditures for a 30-day buprenorphine prescription among privately insured adults from 2003 to 2015. Results New and total buprenorphine users increased dramatically from 2003 to 2013 and plateaued. Total buprenorphine spending was stable from 2003 to 2008, increased from 2009 to 2013, and declined from 2013 to 2015. Out-of-pocket expenditures steadily decreased from $67 in 2003 to $32 in 2015 for a 30-day prescription. Conclusions Buprenorphine treatment costs were stable for health plans and declined for privately insured adults since 2003. Identifying remaining barriers to addressing the opioid addiction treatment gap is a priority.

show abstract

“…For services with coinsurance instead of copayments, we used the total expenditures in the MEPS data and applied coinsurance. All spending was adjusted to 2014 levels using service‐specific medical and prescription drug price indices recommended by MEPS (Agency for Health Care Research and Quality ; Dunn, Grosse, and Zuvekas ) .…”

Section: Methodsmentioning

confidence: 99%